Q4 2021 Results
Company overview
Pharmaceuticals
Participants
Financial performance
Novartis pipeline in Phase 3
Oncology
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Innovation: Clinical trials
8 lead indications
Lead indication
Code
Name
AAA617
177Lu-PSMA-617
AAA6011) Lutathera®
Mechanism
Indication(s)
Radioligand therapy target PSMA mCRPC, pre-taxane
Metastatic hormone sensitive prostate cancer (mHSPC)
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
BCR-ABL inhibitor
BRAF inhibitor + MEK inhibitor
Thrombopoietin receptor
(TPO-R) agonist
Met inhibitor
ABL001
ScemblixⓇ
ACZ885
canakinumab
IL-1b inhibitor
BYL719
Piqray®
PI3Ka inhibitor
CTL019
KymriahⓇ
CD19 CAR-T
DRB436
Tafinlar® + Mekinist®
ETB115
Promacta®
INC280
Tabrecta®
JDQ443 JDQ443
KRAS inhibitor
LEE011
Kisqali®
CDK4 Inhibitor
LNP023
iptacopan
CFB inhibitor
MBG453
sabatolimab
TIM3 antagonist
NIS793
VDT482
NIS793
TGFB1 inhibitor
tislelizumab
PD1 inhibitor
YTB323
YTB323
CD19 CAR-T
tumors (GEP-NET 1L G3)
Chronic myeloid leukemia, 1st line
NSCLC, adjuvant
HER2+ adv BC
Triple negative breast cancer Ovarian cancer
1L high risk acute lymphocytic leukaemia, pediatrics & young adults
Thyroid cancer
r/r Severe aplastic anemia
Non-small cell lung cancer
2/3L Non-small cell lung cancer
HR+/HER2- BC (adj)
Paroxysmal nocturnal haemoglobinuria
Atypical haemolytic uraemic syndrome
Myelodysplastic syndrome
Pancreatic cancer
1L Nasopharyngeal Carcinoma
1L ESCC
1L Hepatocellular Carcinoma
1L Bladder Urothelial Cell Carcinoma
2L Diffuse large B-cell lymphoma³)
Neuroscience
Name
Code
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064
Mechanism
CGRPR antagonist
S1P1,5 receptor modulator
remibrutinib
BTK inhibitor
OAV101 AVXS-101
OMB157 KesimptaⓇ
Respiratory & Allergy
Code
Name
IGE025 XolairⓇ
QGE031 ligelizumab
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
Indication(s)
Mechanism
IgE inhibitor
Food allergy
Auto-injector
IgE inhibitor
Food allergy
Indication(s)
Cardiovascular, Renal, Metabolism
Name
Mechanism
siRNA (regulation of LDL-C)
Angiotensin receptor/neprilysin
inhibitor
Congestive heart failure, pediatrics²)
Code
KJX839 Leqvio®
LCZ696 Entresto®
Non-small cell lung cancer
LNP023 iptacopan
CFB inhibitor
TQJ230
Pelacarsen
ASO targeting Lp(a)
1L Small Cell Lung Cancer
1L Gastric cancer
Localized ESCC
Biosimilars
CVRR-LDLC
IgA nephropathy
Hyperlipidemia, pediatrics
C3 glomerulopathy
Secondary prevention of cardiovascular events in patients with
elevated levels of lipoprotein (a) (CVRR-Lp(a))
Code
Immunology
Code
AIN457
Name
Cosentyx®
Mechanism
IL17A inhibitor
Indication(s)
Lupus Nephritis
Name
GP2411 denosumab
SOK583 aflibercept
Mechanism
anti RANKL mAb
VEGF inhibitor
Indication(s)
Osteoporosis (same as originator)
Ophthalmology indication (as originator)
AS H2H
Psoriatic arthritis (IV formulation)
Axial SpA (IV formulation)
Giant cell arteritis
Hidradenitis suppurativa
Ophthalmology
QGE031
Code
Name
RTH258 BeovuⓇ
Mechanism
VEGF inhibitor
ligelizumab
IgE inhibitor
Indication(s)
Diabetic retinopathy
LOU064 remibrutinib
BTK inhibitor
Chronic spontaneous urticaria
Chronic inducible urticarial (CINDU)
Chronic spontaneous urticaria
Global Health
Code
COA566
Name
Coartem®
Mechanism
Indication(s)
Malaria, uncomplicated (<5kg patients)
1. 177 Lu-dotatate in US. 2. Approved in US.
62 Investor Relations | Q4 2021 Results
3. Ph3 to be initiated in 2022.
U NOVARTIS | Reimagining MedicineView entire presentation